HCC in the Setting of Hepatitis B: Asia-Pacific Considerations

In these slides, expert faculty discusses Asia-Pacific considerations relevant to patients with HCC in the setting of hepatitis B.
Grace LH Wong, MD
Format: Microsoft PowerPoint (.ppt)
File Size: 691 KB
Released: June 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Educational grant provided by:
Gilead Sciences, Inc.

Related Content

Clinical Care Options (CCO) expert commentary from Maria Buti, MD, on her approach to assessing patients with HBV for treatment candidacy in the setting of other host factors.

Maria Buti, MD Released: August 26, 2021

Clinical Care Options (CCO) expert commentary from George Lau, MD, on the importance of screening patients for hepatitis B prior to immunosuppressive therapy initiation

George Lau, MBBS (HKU), MD (HKU), FRCP (Edin, Lond), FAASLD (USA) Released: August 23, 2021

Dr. Takeshi Saito on increasing detection of HBV/HDV coinfection, especially among HBsAg-positive persons, examples from Mongolian population in California from Clinical Care Options (CCO)

person default Takeshi Saito, MD, PhD Physicians: maximum of 0.25 AMA PRA Category 1 Credits Registered Nurses: 0.25 Nursing contact hours Pharmacists: 0.25 contact hours (0.025 CEUs) Released: August 20, 2021 Expired: August 19, 2022

Clinical Care Options (CCO) expert commentary on optimal timing for MTCT prophylaxis in pregnant women with chronic HBV

Joseph Ahn, MD, MS, MBA Released: July 13, 2021

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue